Clinical Infections by Herpesviruses in Patients Treated with Valproic Acid: A Nested Case-Control Study in the Spanish Primary Care Database, BIFAP by Gil, Miguel et al.
Journal of
Clinical Medicine
Article
Clinical Infections by Herpesviruses in Patients
Treated with Valproic Acid: A Nested Case-Control
Study in the Spanish Primary Care Database, BIFAP
Miguel Gil 1,*, Rocío González-González 1 , Angela Vázquez-Calvo 2,
Arturo Álvarez-Gutiérrez 1, Miguel A. Martín-Acebes 3 , Beatriz Praena 2,4 ,
Raquel Bello-Morales 2,4, Juan-Carlos Saiz 3 , Jose A. López-Guerrero 2,4, Enrique Tabarés 5 and
Francisco Sobrino 2,*
1 BIFAP, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and
Medical Devices (AEMPS), 28022 Madrid, Spain; rogogo@gmail.com (R.G.-G.);
aalvarez_externo@aemps.es (A.Á.-G.)
2 Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain;
angelavazquezcalvo@gmail.com (A.V.-C.); bpraena@cbm.csic.es (B.P.);
raquel.bello-morales@inv.uam.es (R.B.-M.); jal@cbm.uam.es (J.A.L.-G.)
3 Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INA),
28040 Madrid, Spain; martin.mangel@inia.es (M.A.M.-A.); jcsaiz@inia.es (J.-C.S.)
4 Universidad Autónoma de Madrid, Departamento de Biología Molecular, Edificio de. Biología, Darwin 2,
Cantoblanco, 28049 Madrid, Spain
5 Universidad Autónoma de Madrid, Facultad de Medicina, Arzobispo Morcillo 4, 28029 Madrid, Spain;
enrique.tabares@uam.es
* Correspondence: mgilg@aemps.es (M.G.); fsobrino@cbm.csic.es (F.S.); Tel.: +34-91-8335347 (M.G.);
+34-91-1964493 (F.S.)
Received: 6 August 2019; Accepted: 9 September 2019; Published: 11 September 2019


Abstract: The objective of this study is to evaluate the risk of clinical infections by herpesviruses in
patients exposed to valproic acid (VPA). We performed a case-control study nested in a primary cohort
selected from the Spanish primary care population-based research database BIFAP (Base de datos para
la Investigación Farmacoepidemiológica en Atención Primaria) over the period 2001–2015. The events
of interest were those diseases caused by any herpesviruses known to infect humans. For each
case, up to 10 controls per case matched by age, gender, and calendar date were randomly selected.
A conditional logistic regression was used to compute adjusted odds ratios (OR) and their 95%
confidence intervals (95% CI). Current use of VPA was associated with a trend towards a reduced risk
of clinical infections by herpesviruses as compared with non-users (OR 0.84; CI 95% 0.7–1.0; p = 0.057).
Among current users, a trend to a decreased risk with treatment durations longer than 90 days was
also observed. The results show a trend to a reduced risk of clinical infection by herpesviruses in
patients exposed to VPA. These results are consistent with those in vitro studies showing that, in
cultured cells, VPA can inhibit the production of the infectious progeny of herpesviruses. This study
also shows the efficient use of electronic healthcare records for clinical exploratory research studies.
Keywords: BIFAP; valproic acid; herpesvirus infections; case-control study; electronic health
care database
1. Introduction
Information derived from databases containing electronic health records (EHR) is increasingly
being used to conduct pharmacoepidemiologic research. EHRs’ usage is broad, including safety
surveillance, comparative effectiveness, drug utilization, and so on [1]. A potential and less developed
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use of EHRs is the study of new indications of drugs already marketed, either to translate findings in basic
research into medical practice (translational research) or to support findings in other clinical studies.
Short chain fatty acid valproic acid (VPA) is an active substance commonly used in epilepsy
and other psychiatric and neurological disorders, including bipolar disorder, neuropathic pain, and
migraine [2]. VPA and related substances with licensed products in Spain are valproate sodium and
valpromide. In vitro studies have shown that VPA inhibits the production of infectious progeny of a
broad spectrum of enveloped viruses causing human and veterinary diseases, which likely reflects a
VPA-mediated impairment of lipid metabolism that may affect different steps of a virus life cycle [3–9].
Enveloped viruses include a broad range of virus families. Among them, Herpesviridae is a
large family of DNA viruses including different species that cause diseases in humans with a high
burden of disease, such as herpes simplex virus (HHV-1 and HHV-2) causing orolabial and genital
herpes, varicella zoster virus causing varicella, or diseases caused by infections by Epstein–Barr virus
(mononucleosis/some cancers) and cytomegalovirus.
VPA doses usually administered to humans are dependent on the body mass, with a therapeutic
range for epilepsy treatment of 50 to 100 mg/liter (about 0.3 to 0.6 mM) in plasma. Some studies have
shown the possibility of the therapeutic antiviral use of the VPA based on its half maximal inhibitory
concentration (IC50) and selectivity index (SI) [9]. Indeed, an IC50 of 0.55 mM has been determined for
VPA inhibition of HHV-1 in human oligodendroglioma (HOG) cultured cells, which is compatible
with a potential in vivo antiviral effect of VPA [4].
In spite of in vitro findings, to the best of our knowledge, no clinical studies in humans are
available testing the hypothesis of an antiviral effect of the VPA.
The objective of this study is to evaluate the risk of clinical infections by the viruses of the family
Herpesviridae (herpesviruses) in patients exposed to VPA in the Spanish research database BIFAP
(Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria).
2. Experimental Section
2.1. Data Source Description
The study was performed in the Spanish primary care population-based research database BIFAP.
BIFAP is a non-profit program of the Spanish Agency of medicines and medical devices in collaboration
with nine autonomous regions of Spain (www.bifap.org) [10]. The BIFAP research database for the year
2014 includes anonymized data from over 7.6 million patients prospectively and routinely registered
in the electronic healthcare records (EHR) by 5714 primary care physicians (PCPs), both general
practitioners and pediatricians, over the period 2001–2015. The mean follow-up of patients included in
BIFAP database is 5.1 years, totalling 38.6 million person-years of follow-up. BIFAP is comparable
to the Spanish population with respect to its age and sex distribution, covering 17.0% of the total
Spanish population. BIFAP has been validated for pharmacoepidemiologic research through multiple
studies [10] and successfully compared to other well-known European databases [11–14].
The information recorded in BIFAP includes demographic data, clinical data, drug prescriptions,
referrals to specialists, clinical notes as free-text, and other additional health data (i.e., test results,
interventions, lifestyle information). Prescriptions are coded according to the Anatomical Therapeutic
Classification (ATC), and the following data are recorded: product name, date of prescription, quantity
prescribed, dose regime, and duration of drug therapy.
2.2. Study Design
We performed a case-control study nested in a primary cohort selected from BIFAP over the period
1 January 2001 to 31 December 2015. The study cohort included those patients aged 100 years or lower,
with at least two years of continuous enrolment with the primary care physician. Each patient started
his/her follow-up in the study cohort when he/she met those criteria (start date). We were interested
in the first ever episodes of the events of interest among new users of VPA in the study period [15].
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Thus, patients were excluded from the study cohort if they had, previous to the start date of follow-up,
a registry of clinical infections by herpesviruses, varicella vaccination registry, or a prescription of
an antiepileptic drug. Likewise, patients with a previous history of cancer were excluded given their
characteristics and the likely lack of exhaustive information in primary care records.
The population of the study cohort (n = 5,858,722) was then followed-up until the earliest
occurrence one of the following: incident disease caused by any of the different herpesviruses assessed
(event of interest), 101 years old, cancer diagnosis, death, varicella vaccination registry, end of follow-up
of the patient, or end of the study period.
2.3. Case Identification
The events of interest were those diseases caused by any of the herpesviruses known to infect
humans, specifically the following:
• Orolabial herpes and genital herpes: caused by HHV-1 and 2 (herpes simplex virus);
• Varicella: caused by HHV-3 (varicella-zoster virus);
• Infectious mononucleosis: caused by HHV-4 (Epstein–Barr virus) or HHV-5 (human cytomegalovirus);
• Roseola infantum: caused by HHV-6;
• Kaposi’s sarcoma: caused by HHV-8 (Kaposi’s sarcoma-associated herpesvirus).
Clinical data are coded in BIFAP in accordance with two diagnostic coding systems: the
International Classification of Primary Care (ICPC) and the International Classification of Diseases
(ICD-9). The ICPC dictionary is used in most of the autonomous communities involved in BIFAP and
its granularity is limited (686 codes), as compared with the ICD-9 dictionary (23,222 codes). For ICPC,
a more granular dictionary is available for research purposes in BIFAP (ICPC-BIFAP). The detailed
description of the procedures to build the ICPC-BIFAP is included in Appendix A.
Case-finding algorithms (CFA) were built for each of the events of interest based on proper
code selection in those dictionaries plus text-mining strategies. In Appendix B, the specific ICD-9
codes (Table A1), ICPC-BIFAP codes (Table A2), and string text search criteria (Table A3) are detailed.
The first registry of any of the above mentioned events of interest during the follow-up was identified
to be used as case in the study, and the recorded date of that event was considered as the index date for
the study.
Additional text-mining techniques were performed in the clinical notes linked to the diagnosis, in
order to identify non-cases among those events selected by the defined case-finding algorithm (false
positives). Text mining included a broad search of semantic terms related to “vaccination”, “previous
history”, “relatives”, “exposure/contact”, and so on. Clinical profiles of the cases meeting these criteria
were reviewed manually and those confirmed as non-cases were disregarded for the study.
2.4. Selection of Controls
Up to 10 controls per case matched by age (+/− 1 year), gender, and calendar date were randomly
selected from the risk set for each case (risk set sampling). Accordingly, a subject might be selected as
control before being a case and might be selected as a control for more than one case. The date of the
herpesvirus infection (case) was considered as the index date for the matched controls.
2.5. Exposure Definition
Exposure of interest included VPA and related substances (sodium valproate and valpromide).
We categorized cases and controls as current users when the supply of prescription finished
within 30 days before the date of the herpesvirus infection or the corresponding date for the matched
controls (index dates); recent users when supply finished between 31 and 365 days before the index
date; past users when supply finished more than one year before the index date; and nonusers when
there was no recorded prescription ever.
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The effect of treatment duration among current users was also evaluated. We considered
prescriptions to be consecutive when the time elapsed between the end of supply of one prescription
and the start of the next was 90 days or less. Continuous duration was categorized into the following
time-windows: <91 days, 91–365 days, and >365 days.
2.6. Potential Confounding Variables
Potential confounding variables considered for the analysis included the previous history of
the following comorbidities and risk factors any time previous to the index date of cases and
matched controls:
• Diseases affecting the immune system; Human Immunodeficiency Virus (HIV) infection,
other immunodeficiencies;
• Chronic diseases impairing health conditions: asthma, chronic obstructive pulmonary disease,
ischaemic heart disease, stroke, diabetes mellitus, heart failure, hypertension, hyperlipidemia,
chronic hepatitis, chronic renal failure, and Alzheimer disease;
• Lifestyle conditions: alcohol abuse, smoking, body mass index, and obesity;
• Diseases related to the potential use of VPA: depression, neuropathic pain, epilepsy, bipolar
disorder, and migraine;
• Comedications: systemic corticosteroids, systemic antiviral drugs, immunosuppressant,
antibiotics, anxiolytics, antipsychotic drugs, and antiepileptic drugs other than VPA.
• The number of visits to the PCP (<6, 6–15, 16–24, >24) was ascertained in the two-year period
before the index date.
2.7. Statistical Analysis
Cases and controls were matched by age, sex, and index date. We used conditional logistic
regression to compute adjusted odds ratios (OR) and their 95% confidence intervals (95% CI) for
infection by herpesviruses associated to the use of VPA after adjusting for the potential confounders
described above.
As sensitivity analysis, separate analyses were also performed to assess the association for
the different herpesviruses grouped according the following human diseases: orolabial/genital
(HHV-1/HHV-2); varicella/herpes zoster (HHV-3); infectious mononucleosis (HHV-4/HHV-5); roseola
infantum (HHV-6), and Kaposi’s sarcoma (HHV-8).
In addition, the effect of valpromide, a VPA derivate, was also evaluated separately in order to
test if a differential effect was observed.
The level of statistical significance was p < 0.05. Statistical analyses were performed using Stata
(version 15, StataCorp LLC, College Station, TX, USA).
2.8. Ethics Review
The scientific committee of BIFAP granted a positive opinion of the study protocol (#08/2015).
The investigators had access to only fully anonymized data and, under this condition, no specific
ethics review was required according to Spanish law.
3. Results
3.1. Characteristics of the Study Cohort, Validation, and Incidence of Clinical Infections by Herpesviruses in
BIFAP Database
The study cohort was made up of 5,858,722 patients, totalling 24,932,043 person-years (py) of
follow-up. With the initial computer search (BIFAP case-finding algorithms), 214,645 potential cases
were retrieved. Among them, 10,698 were excluded after additional validation using text mining
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strategies in the clinical notes linked to the diagnosis. The resulting number of valid cases for the study
was of 203,947. The flowchart for the selection of cases is displayed in Figure 1.
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Figure 1. Flow chart showing the identification processes of cases and controls in the Base de datos
para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP) database.
Most of the valid cases of clinical infections by herpesviruses included in the study were those
produced by HHV-1/HHV-2 or HHV-3 causing orolabial/genital herpes and varicella, respectively, in
humans (see Table 1).
Table 1. Herpesvirus infections type distribution for cases and controls.
Herpes Virus Type Disease in Humans Controls(N = 2,039,466)
Cases
(N = 203,947)
HHV-1/HHV-2 Oral/genital herpes 1,018,000 (49.9%) 101,800 (49.9%)
HHV-3 Varicella/herpes zoster 869,906 (42.7%) 86,991 (42.7%)
HHV-4/HHV-5 Infectious mononucleosis 146,030 (7.2%) 14,603 (7.2%)
HHV-6 Roseola infantum 5390 (0.3%) 539 (0.3%)
HHV-8 Kaposi’s sarcoma 140 (0.007%) 14 (0.007%)
HHV: Herpesviruses.
The resulting incidence of clinical infectio s by herpesviruses in the BIFAP database was 8. per
1000 erson-years of follow-up. This incidence was higher for orolabial/genital herpes (4.1 per 1000 py)
and varicella/herpes Zoster (3.5 per 1000 py) infections, respectively.
3.2. Characteristics of Cases and Controls Included in the Study
Our study population included 203,947 cases and 2,039,466 controls. Most cases were
infections caused by HHV-1/HHV-2 (49.9%) and HHV-3 (42.7%), causing orolabial/genital herpes
and varicella/herpes zoster simple, respectively (see Table 1). Among these cases, 58.4% were male
and 43.5% were younger than 10 years old (see Table 2). The cases, in general, presented a greater
proportion of comorbidities and drug use than controls. The distribution of cases and controls at the
index date of demographic characteristics (matching variables), lifestyle/comorbidities, and previous
use of medications are shown in Tables 2–4, respectively.
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Table 2. Age and sex distribution (matching variables) of cases and controls.
Sociodemographic
Variable Categories
Cases (n (%)) N =
203,947
Controls (n (%))
N = 2,039,466
Age
0 year 122,452 (6%) 9317 (4.57%)
1–4 years 529,832 (25.98%) 56,789 (27.84%)
5–9 years 233,747 (11.46%) 22,660 (11.11%)
10–17 years 135,515 (6.64%) 13,465 (6.6%)
18–44 years 557,298 (27.33%) 55,627 (27.28%)
45–64 years 283,505 (13.9%) 28,318 (13.88%)
65–74 years 103,221 (5.06%) 10,361 (5.08%)
75+ 73,896 (3.62%) 7410 (3.63%)
Gender
Male 1,190,590 (58.38%) 119,059 (58.38%)
Female 848,876 (41.62%) 84,888 (41.62%)
Cases and controls were matched by age and sex.
Table 3. Lifestyle and comorbidities distribution between cases and controls.
Lifestyle/Comorbidities Categories Cases (n (%)) N =203,947
Controls (n (%))
N = 2,039,466 Crude OR (95%CI)
Number of visits to the
PCP (last 3 years)
1–5 686,728 (33.67%) 26,081 (12.79%) 1 (ref)
6–15 696,274 (34.14%) 73,880 (36.23%) 3.14 (3.09–3.18)
16–24 332,186 (16.29%) 46,920 (23.01%) 4.85 (4.77–4.93)
25+ 324,278 (15.9%) 57,066 (27.98%) 6.78 (6.67–6.90)
Smoking
Non smoker 271,264 (13.3%) 30,853 (15.13%) 1 (ref)
Ex-smoker 27,752 (1.36%) 3673 (1.8%) 1.19 (1.14–1.23)
Current smoker 194,223 (9.52%) 20,395 (10%) 0.92 (0.90–0.94)
Missing information 1,546,227 (75.82%) 149,026 (73.07%) 0.81 (0.80–0.83)
Alcohol consumption No 1,533,808 (75.21%) 147,434 (72.29%) 1 (ref)
Yes 505,658 (24.79%) 56,513 (27.71%) 1.24 (1.23–1.26)
Chronic obstructive
pulmonary disease
No 2,021,282 (99.11%) 201,892 (98.99%) 1 (ref)
Yes 2055 (1.01%) 18,184 (0.89%) 1.14 (1.09–1.20)
Asthma
No 181,273 (88.88%) 1,874,907 (91.93%) 1 (ref)
Yes 164,559 (8.07%) 22,674 (11.12%) 1.44 (1.42–1.46)
Ischaemic heart disease
No 2,019,995 (99.05%) 201,768 (98.93%) 1 (ref)
Yes 19,471 (0.95%) 2179 (1.07%) 1.13 (1.08–1.18)
Cerebrovascular accident
No 2,022,049 (99.15%) 202,073 (99.08%) 1 (ref)
TIA 12,405 (0.61%) 1233 (0.6%) 1 (0.94–1.06)
Stroke 5012 (0.25%) 641 (0.31%) 1.29 (1.18–1.40)
Diabetes Mellitus
No 1,973,842 (96.78%) 197,431 (96.81%) 1 (ref)
Yes 65,624 (3.22%) 6516 (3.19%) 0.99 (0.96–1.02)
Heart failure
No 2,032,388 (99.65%) 203,246 (99.66%) 1 (ref)
Yes 7078 (0.35%) 701 (0.34%) 0.99 (0.91–1.07)
Hypertension No 1,856,925 (91.05%) 184,572 (90.5%) 1 (ref)
Yes 182,541 (8.95%) 19,375 (9.5%) 1.11 (1.09–1.14)
Hyperlipidemia No 1,845,499 (90.49%) 181,358 (88.92%) 1 (ref)
Yes 193,967 (9.51%) 22,589 (11.08%) 1.28 (1.25–1.30)
Chronic renal disease
No 2,032,754 (99.67%) 203,196 (99.63%) 1 (ref)
Yes 6712 (0.33%) 751 (0.37%) 1.12 (1.04–1.21)
AIDS/ HIV+ No 2,037,298 (99.89%) 203,427 (99.75%) 1 (ref)
Yes 2168 (0.11%) 520 (0.25%) 2.41 (2.19–2.66)
Chronic hepatitis No 2,034,550 (99.76%) 203,355 (99.71%) 1 (ref)
Yes 4916 (0.24%) 592 (0.29%) 1.21 (1.11–1.31)
Alzheimer disease
No 2,032,190 (99.64%) 203,350 (99.71%) 1 (ref)
Yes 7276 (0.36%) 597 (0.29%) 0.81 (0.74–0.88)
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Table 3. Cont.
Lifestyle/Comorbidities Categories Cases (n (%)) N =203,947
Controls (n (%))
N = 2,039,466 Crude OR (95%CI)
Immunodeficiency No 2,038,212 (99.94%) 203,744 (99.9%) 1 (ref)
Yes 1254 (0.06%) 203 (0.1%) 1.62 (1.40–1.88)
Depression No 1,854,589 (90.94%) 179,097 (87.82%) 1 (ref)
Yes 184,877 (9.06%) 24,850 (12.18%) 1.49 (1.47–1.51)
Neuropathic pain No 2,030,151 (99.54%) 202,443 (99.26%) 1 (ref)
Yes 9315 (0.46%) 1504 (0.74%) 1.63 (1.54–1.72)
Epilepsy No 2,025,726 (99.33%) 202,001 (99.05%) 1 (ref)
Yes 13,740 (0.67%) 1946 (0.95%) 1.43 (1.36–1.50)
Bipolar disorder No 2,038,214 (99.94%) 203,782 (99.92%) 1 (ref)
Yes 165 (0.08%) 1252 (0.06%) 1.32 (1.12–1.55)
Migraine No 197,068 (96.63%) 1,990,109 (97.58%) 1 (ref)
Yes 6879 (3.37%) 49,357 (2.42%) 1.43 (1.39–1.46)
OR: Odds ratio; 95%CI: 95% confidence interval; ref: reference category; PCP: Primary Care Physician; TIA: Transient
Ischaemic Attack; HIV: Human Immunodeficiency Virus; AIDS: Adquired Immune Deficiency Syndrome.
Table 4. Previous medication use between cases and controls
Previous
Medications Categories
Cases (n (%)) N =
203,947
Controls (n (%))
N = 2,039,466
Crude OR (95%
CI)
Corticoids for
systemic use
(Glucocorticoids)
Non use 1,756,946 (86.15%) 162,552 (79.7%) 1 (ref)
0–30 days 23,529 (1.15%) 3688 (1.81%) 1.76 (1.69–1.82)
31–365 97,827 (4.8%) 14,787 (7.25%) 1.7 (1.67–1.73)
365+ 161,164 (7.9%) 22,920 (11.24%) 1.6 (1.57–1.62)
Antivirals for
systemic use
Non use 2,025,268 (99.3%) 200,749 (98.43%) 1 (ref)
0–30 days 723 (0.04%) 291 (0.14%) 4.09 (3.57–4.68)
31–365 3843 (0.19%) 888 (0.44%) 2.35 (2.18–2.53)
365+ 9632 (0.47%) 2019 (0.99%) 2.14 (2.04–2.25)
Immunosuppressants
Non use 2,035,287 (99.8%) 203,157 (99.61%) 1 (ref)
0–30 days 2265 (0.11%) 490 (0.24%) 2.17 (1.97–2.39)
31–365 719 (0.04%) 134 (0.07%) 1.87 (1.56–2.25)
365+ 1195 (0.06%) 166 (0.08%) 1.4 (1.19–1.64)
Antibacterials for
systemic use
Non use 777,879 (38.14%) 45,965 (22.54%) 1 (ref)
0–30 days 136,679 (6.7%) 25,353 (12.43%) 3.37 (3.31–3.43)
31–365 541,039 (26.53%) 75,211 (36.88%) 2.52 (2.48–2.55)
365+ 583,869 (28.63%) 57,418 (28.15%) 1.75 (1.73–1.78)
Anxiolytics
Non use 1,669,397 (81.85%) 153,836 (75.43%) 1 (ref)
0–30 days 76,617 (3.76%) 11,381 (5.58%) 1.84 (1.80–1.88)
31–365 103,121 (5.06%) 17,975 (7.34%) 1.70 (1.67–1.73)
365+ 190,331 (9.33%) 23755 (11.65%) 1.45 (1.43–1.48)
Antipsychotics
Non use 1,950,135 (95.62%) 191,695 (93.99%) 1 (ref)
0–30 days 11,729 (0.58%) 1267 (0.62%) 1.13 (1.07–1.20)
31–365 21,457 (1.05%) 3094 (1.52%) 1.51 (1.46–1.57)
365+ 56,145 (2.75%) 7891 (3.87%) 1.48 (1.44–1.52)
Antiepileptic drugs
(other than
valproic acid)
Non use 2,012,359 (98.67%) 199,751 (97.94%) 1 (ref)
0–30 days 8786 (0.43%) 1307 (0.64%) 1.52 (1.44–1.62)
31–365 7572 (0.37%) 1243 (0.61%) 1.68 (1.58–1.79)
365+ 10,749 (0.53%) 1646 (0.81%) 1.57 (1.49–1.66)
OR: Odds ratio; 95%CI: 95% confidence interval; ref: reference category.
3.3. Risk of Clinical Infection by Herpesviruses Associated to the Use of VPA
Current use of VPA was associated with a trend to a reduced risk of clinical infection by
herpesviruses as compared with non-users (OR 0.84; 95% CI 0.7–1.0, p = 0.057). This trend was also
observed for those who abandon the medication in the first year (recent use OR 0.79; CI 95% 0.60–1.02,
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p = 0.071). Among current users, a trend to a decreased risk with treatment durations longer than 90
days was observed, being statistically significant for durations longer than one year (OR 0.68; 95% CI
0.48–0.95, p = 0.02) (see Table 5).
Table 5. Use of valproic acid and risk of clinical infections by herpesviruses.
CASES
n = 203,947
CONTROLS
n = 2,039,466
Non-Adjusted OR
† (95%CI)
Adjusted OR ‡
(95%CI)
Exposure
Non use 203,644 (99.9%) 2,037,218 (99.9%) 1 (ref) 1 (ref)
Current use (0–30 days) 148 (0.1%) 1076 (0.1%) 1.38 (1.16–1.63) 0.84 (0.70–1.00)
Recent use (31–365 days) 65 (0.0%) 540 (0.0%) 1.20 (0.93–1.55) 0.79 (0.60–1.02)
Past use (>365 days) 90 (0.0%) 632 (0.0%) 1.42 (1.14–1.78) 0.94 (0.75–1.18)
Continuous duration *
Non use 203,644 (99.9%) 2,037,218 (99.9%) 1 (ref) 1 (ref)
<91 days 52 (35.1%) 331 (30.8%) 1.57 (1.17–2.10) 1.02 (0.75–1.37)
91–365 days 57 (38.5%) 415 (38.6%) 1.37 (1.04–1.81) 0.83 (0.63–1.11)
>365 days 39 (26.4%) 330 (30.7%) 1.18 (0.85–1.64) 0.68 (0.48–0.95)
Exposure includes drugs containing valproic acid or related substances (sodium valproate or valpromide); OR:
Odds ratio; 95%CI: 95% confidence interval; ref: reference category; †. crude model matched by age, sex, and
month/year of the event; ‡. model adjusted by all variables included in Table 3; Table 4; *. Among current users.
Concerning the risk of the diverse clinical diseases caused by the different herpesviruses, a
non-statistically significant reduced risk in current users of VPA was observed for orolabial/genital
herpes (OR 0.89; 95% CI 0.70–1.15; p = 0.37) and varicella (OR 0.92; 95% CI 0.68–1.24; p = 0.58) (see
Table 6). Both diseases represent 92.6% of cases included in the study. Separate evaluation was not
feasible for roseola infantum or Kaposi’s sarcoma owing to the low number of exposed cases.
Table 6. Use of valproic acid and risk of clinical infections by different herpesviruses.
HHV-1/HHV-2
OR (95% CI)
HHV-3
OR (95% CI)
HHV-4/HHV-5
OR (95%CI)
Exposure
Non use 1 (ref) 1 (ref) 1 (ref)
Current use (0–30 days) 0.89 (0.70–1.15) 0.92 (0.68–1.24) 0.97 (0.51–1.83)
Recent use (31–365 days) 0.87 (0.61–1.24) 0.80 (0.52–1.24) 0.84 (0.29–2.45)
Past use (>365 days) 1.04 (0.79–1.37) 0.88 (0.54–1.43) 0.79 (0.34–1.81)
Continuous duration†
Non use 1 (ref) 1 (ref) 1 (ref)
<91 days 1.16 (0.77–1.74) 0.92 (0.56–1.52) 1.40 (0.49–4.02)
91–365 days 0.85 (0.56–1.30) 0.87 (0.56–1.36) 1.87 (0.77–4.53)
>365 days 0.71 (0.45–1.12) 0.95 (0.55–1.65) 0.15 (0.02–1.16)
Exposure includes drugs containing valproic acid or related substances (sodium valproate or valpromide). OR: Odds
ratio; 95%CI: 95% confidence interval; HHV-1/HHV-2 (causing orolabial/genital herpes); HHV-3 (varicella/herpes
zoster); HHV-4/HHV-5 (infectious mononucleosis). Results for HHV-6 (roseola infantum) and HHV-8 (Kaposi’s
sarcoma) are not provided separately because models did not converge. Results of all herpes viruses combined are
displayed in Table 5. †. among current users. ref: reference category.
The trend to a decreased risk among current users observed with treatment durations longer than
90 days for all herpesviruses (see Table 5) was only noticed for orolabial/genital herpes (HHV-1/HHV-2)
(see Table 6). For infectious mononucleosis (HHV-4/HHV-5), a non-significant decreased risk was
observed for treatment durations longer than 365 days (OR 0.15; 95% CI 0.02–1.16; p = 0.07) (see
Table 6).
Patients currently exposed to valpromide represent a low percentage (2.6%) of those exposed to
VPA and related substances. Separate results for valpromide showed also a decreased risk of infections
J. Clin. Med. 2019, 8, 1442 9 of 14
by herpesviruses (OR 0.60; 95% CI, 0.18–2.00), although the low number of cases of controls exposed (3
and 30, respectively) led to wide confidence intervals.
4. Discussion
The results of this study show a trend to a reduced risk of clinical infections by herpesviruses in
patients exposed to VPA, especially in those with treatment durations longer than 90 days. This trend
to a reduced risk is consistent across the most frequent herpesviruses infections, although differences
were not statistically significant.
These results are consistent with in vitro studies showing that, in cultured cells, VPA inhibits the
production of infectious progeny of different enveloped viruses causing relevant human and veterinary
diseases [3,5,6,9,16,17] including herpesviruses [4,7,8].
To the best of our knowledge, this is the first epidemiological study designed to test the in vitro
hypothesis of an antiviral effect of VPA. In the context of this translational research, a study was
performed resulting in an IC50 of 0.55 mM for VPA inhibition of HSV-1 in HOG cultured cells, which
is compatible with a potential antiviral effect in vivo of VPA [4]
Several studies have shown that VPA can stimulate the infectivity and replication of enveloped
viruses, including some of the Herpesviridae family studied here [8,18]. Enhancement of herpesvirus
infection has been reported in cells competent for Human type I interferons (IFN) induction upon
VPA treatment in a process associated with the VPA-mediated inhibition of type I histone deacetylases
(HDAC) [19–21]. Histone deacetylation is required for expression of IFN-stimulated genes (ISGs) [22].
Consistently, HADC inhibition by VPA results in ISGs’ downregulation and a decrease in type I
IFN response [23]. However, the present analysis does not support an increase of the incidence of
herpesvirus infections in patients treated with VPA, but is consistent with the proposed inhibitory
effect of VPA on the infection of herpesviruses [4].
The results of our epidemiological study are consistent, and extend to humans, with previous
reports on the in vivo potential of VPA and its derivative valpromide—which lacks the free carboxylic
group and the HADC inhibitory activity—to interfere with herpesvirus multiplication in mice [7].
Hence, a trend to a protective effect in human patients was observed for both compounds, although
the decreased risk observed was marginally significant only for VPA (p = 0.053). Separate estimations
for valpromide were based in a few number of cases and controls exposed, leading to wide
confidence intervals.
Interestingly, the trend towards a protective effect observed extends to the most common diseases
caused by the different herpesviruses like orolabial/genital herpes and varicella, although differences
were not statistically significant because of the limited number of exposed events (see Table 6).
Varicella represents 42.7% of cases in the study. The incidence of varicella in BIFAP (4.1 per 1000 py)
was comparable to that reported to the Spanish network of epidemiological surveillance [24], suggesting
an exhaustive registration of Varicella in the BIFAP database. The Spanish Association of Pediatricians
has recommended varicella vaccination for all children since the year 2000. Nevertheless, varicella
vaccination was not included in the official vaccination calendar in Spain until the year 2016, being
fully financed by the Spanish National Health Service in the year 2018 [25]. Thus, a substantial decrease
in the burden of disease is expected for the coming years in Spain.
Regarding the effect of VPA treatment duration, the trend to a decreased risk among current users
with treatment durations longer than 90 days observed for all herpesviruses (see Table 5) was only
noticed for orolabial/genital herpes and, to a lesser extent, for infectious mononucleosis (see Table 6),
although differences were not statistically significant. Thus, VPA might have different functions on
multiple types of herpesviruses and their associated diseases, although further study is necessary to
confirm this hypothesis.
Most herpesviruses infections are asymptomatic and seroconversion rates in humans are high.
Multiple factors might be involved to develop clinical disease among those infected, but asymptomatic
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patients. Also, VPA itself might, theoretically, have a role in this, although neither previous hypothesis
nor potential mechanisms have been reported.
The patient’s seroconversion status is not usually available in clinical EHR and the events caused
by herpesviruses evaluated in this study are only those with clinical symptoms. Consequently, the
statistical analysis cannot be additionally adjusted/stratified by asymptomatic infection. Nevertheless,
given the previous considerations, an imbalance in the proportion of patients with an asymptomatic
infection among cases and controls regarding exposure status is not expected.
The combined evidence of in vitro studies, IC50, and epidemiological studies/data supports a
potential therapeutic antiviral use of VPA to treat infections caused by herpesviruses. The trend to a
protective effect of VPA in human patients found is marginally significant and, given the observational
nature of the study, the possibility of residual confounding by unmeasured factors cannot be ruled out.
Thus, further research is needed to confirm these findings.
However, any further development or study to evaluate the therapeutic effect of VPA is jeopardized
by the risk of neurodevelopmental disorders and congenital malformations in children exposed
intra-utero to VPA [26]. Given the great public impact of some of the diseases caused by enveloped
virus and the potential protective effect of VPA on the risk of herpesviruses infections in the general
population, it might be helpful to understand the mechanism behind these protective effects and to
explore the finding of safer related compounds.
In summary, this study demonstrates that well-organized and updated databases from health
records could be efficiently used for clinical exploratory studies in order to investigate the potential
secondary use of drugs already in clinical practice and design targeted clinical trials
5. Conclusions
In conclusion, the current study shows how translational research is helpful in order to strengthen
in vitro hypotheses in humans using electronic health care records, and suggest a potential effect of
VPA on clinical diseases caused by an enveloped virus of the Herpesviridae family.
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Appendix A Procedures to Build the ICPC-BIFAP Medical Terms Dictionaries
Currently, two coding systems, with different levels of granularity, coexist in BIFAP: the
International Classification of Primary Care (ICPC) and the International Classification of Diseases
(ICD-9). The ICPC is the coding system for eight out of nine participant Autonomous Regions and its
granularity is limited as compared with ICD-9 (686 vs. 23,222 codes, respectively).
To identify the episode of interest by the primary care physician (PCP), the EHR software contains
an internal thesaurus, where a list of descriptors of diseases, signs, or symptoms is linked to the
different dictionary codes. Often, these descriptors provide more detailed information than that in the
corresponding code. Likewise, only for ICPC-based EHR software, new descriptors can be included at
the local level, and the PCPs can also modify or add information to the selected episode descriptor.
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This EHR software flexibility results in a huge number of different descriptors in the BIFAP database
(3.4 million).
To standardize this, BIFAP has developed its own research dictionary (ICPC-BIFAP) by adding, to
the most frequently used descriptors, a fourth digit to the original three-digit ICPC code, increasing its
granularity. In 2014, the ICPC-BIFAP dictionary included 5799 indexed terms. ICPC-BIFAP and ICD-9
codes covers about 93.2% of all diagnoses registered in BIFAP (116.7 million).
Concerning the autonomous region coding with ICD-9, given the big granularity of the medical
terms dictionary, information received in BIFAP is already normalized and no further actions are needed.
To ease the management of the events for pharmacoepidemiological studies, specific case-finding
algorithms (CFA) have been developed for an increasing number of outcomes. CFAs include related
codes in both ICD-9 and ICPC-BIFAP dictionaries and might also include laboratory test results,
additional health data, or text mining strategies. Text mining strategies are usually included to build
CFAs given that, as commented previously, 6.8% of diagnoses in BIFAP are not mapped to any of the
ICPC-BIFAP codes available.
Appendix B BIFAP Case-Finding Strategies to Identify Diseases Caused by
Herpesvirus Infections
Table A1. International Classification of Diseases (ICD)-9 codes for diseases caused by herpesviruses.
ICD-9 Code Description
052 Chickenpox
052.0 Postvaricella encephalitis
052.1 Varicella (hemorrhagic) pneumonitis
052.2 Postvaricella myelitis
052.7 Chickenpox with other specified complications
052.8 Chickenpox with unspecified complication
052.9 Varicella without mention of complication
054 Herpex simplex
054.0 Eczema herpeticum
054.1 Genital herpes
054.10 Genital herpes, unspecified
054.11 Herpetic vulvovaginitis
054.12 Herpetic ulceration of vulva
054.13 Herpetic infection of penis
054.19 Other genital herpes
054.2 Herpetic gingivostomatitis
054.3 Herpetic meningoencephalitis
054.4 Herpex simplex with ophthalmic complications
054.40 Herpes simplex with unspecified ophthalmic complication
054.41 Herpes simplex dermatitis of eyelid
054.42 Dendritic keratitis
054.43 Herpes simplex disciform keratitis
054.44 Herpes simplex iridocyclitis
054.49 Herpes simplex with other ophthalmic complications
054.5 Herpetic septicemia
054.6 Herpetic whitlow
054.7 Herpex simplex with other specified complications
054.71 Visceral herpes simplex
054.72 Herpes simplex meningitis
054.73 Herpes simplex otitis externa
054.74 Herpes simplex myelitis
054.79 Herpes simplex with other specified complications
054.8 Herpes simplex with unspecified complication
054.9 Herpes simplex without mention of complication
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Table A1. Cont.
ICD-9 Code Description
075 Infectious mononucleosis
078.5 Cytomegaloviral disease
771.1 Congenital cytomegalovirus infection
058.1 Roseola infantum
058.10 Roseola infantum, unspecified
058.11 Roseola infantum due to human herpesvirus 6
058.12 Roseola infantum due to human herpesvirus 7
058.21 Human herpesvirus 6 encephalitis
058.81 Human herpesvirus 6 infection
058.82 Human herpesvirus 7 infection
Table A2. International Classification of Primary Care (ICPC)-Base de datos para la Investigación
Farmacoepidemiológica en Atención Primaria (BIFAP) codes for diseases caused by herpesviruses.
ICPC Code BIFAP Subcode Description
A77 9 Cytomegalovirus infection
A75 1 Infectious mononucleosis
A75 2 Epstein–Barr virus infection
A72 1 Chickenpox
D83 19 Herpetic stomatitis
D83 20 Herpetic gingivostomatitis
D83 26 Herpetic gingivitis
F16 10 Herpes simplex eyelid
F73 18 Herpes simplex eye
S71 1 Herpex simplex mouth/lip
S71 2 Herpetic whitlow
S71 3 Herpetic infection skin
S71 5 Herpes simplex
X90 1 Herpetic infection genital female
Y72 1 Herpetic infection genital male
Y72 999 Herpetic infection genital & annus male
W71 6 Herpes pregnancy
F73 20 Herpes keratitis
S71 4 Herpes not specified
Table A3. Text mining search strategies.
Specific Strings (in Spanish)
HERPES OR HERPET% OR HERPEX OR CITOMEGALOVIRUS OR CMV OR MONONUCLEOSIS OR
VARICELA * OR EPSTEIN OR ROSEOLA† OR KAPOSI
* Excluded if string text identifying vaccination are also included; † Excluded if string text identifying a syphilitic
etiology are also included.
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